Memory and Antioxidants in Vascular Impairment Trial

Vascular Cognitive Impairment no Dementia Clinical Trial

Official title: Efficacy and Safety of N-acetylcysteine (NAC) in Patients With Mild Vascular Cognitive Impairment

Status Completed

Clinical Trial Summary

This is a 24-week randomized, double-blind, placebo-controlled parallel group design study involving Vascular cognitive impairment-no dementia (VCIND) patients to evaluate the efficacy and safety of oral NAC supplementation (2,400 mg daily) as an add-on therapy to improve cognitive function in patients undergoing cardiac rehabilitation (CR). The CR program consists of a harmonized aerobic and resistance training in a supervised group setting. Eligible patients will be randomized to receive NAC (four 600 mg capsules given as 2 capsules in the morning and 2 capsules in the evening) or matching placebo capsules. The initial NAC dosage will be 600mg/day (one 600mg capsule in the morning) for the first week, followed by 1,200 mg/day (one 600 mg capsule in the morning, one 600mg capsule in the evening) for the second week, followed by 1,800 mg/day (two 600mg capsules in the morning, one 600mg capsule in the evening) for third week, followed by 2,400mg/day (two 600mg capsules in the morning, two 600mg capsules in the evening) for the following 21 weeks.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Cognitive Dysfunction
• Vascular Cognitive Impairment no Dementia

• NCT number: NCT03306979
• Study type: Interventional
• Source: Sunnybrook Health Sciences Centre
• Status: Completed
• Phase: Phase 2
• Start date: April 30, 2018
• Completion date: September 27, 2023